Form 4: SI-BONE Director Timothy Davis Executes Stock Transactions

Director Timothy E. Davis Jr. exercised stock options and sold shares of SI-BONE, Inc. in late May 2026.

Summary

• Director Timothy E. Davis Jr. exercised options to acquire 12,064 shares of common stock at a price of $4.32 per share on May 28, 2026.
• The director subsequently sold a total of 7,280 shares across two days (May 28 and May 29, 2026).
• The sales were executed at weighted average prices of $14.4706 and $14.1394 per share.
• Following these transactions, the director maintains a beneficial ownership of 65,722 shares of SI-BONE common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine insider activity rather than a strategic shift or operational update.

Positives

• The director maintains a significant remaining equity stake of 65,722 shares in the company.
• The exercise of options demonstrates continued participation in the company's equity incentive programs.

Negatives

• The director reduced their total beneficial ownership position through the sale of 7,280 shares.

Risks

• Market volatility may impact the value of the director's remaining holdings.
• Future sales by insiders could be perceived negatively by the market.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions are common in the medical device sector, often related to tax planning or pre-scheduled liquidity events rather than changes in company outlook.

Comparison to Industry Standards

• Insider selling following option exercises is a standard practice for corporate directors in the healthcare and medical technology industries.
• The transaction volume is relatively small compared to the total outstanding shares of SI-BONE, Inc.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction represents a standard exercise and sale by a director.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

SI-BONE, SIBN, Insider Trading, Form 4, Director Transaction, Equity Compensation